Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Efficacy of DuodartTM Versus Watchful Waiting With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Symptomatic BPH

Next Previous
Trial Profile

Comparative Efficacy of DuodartTM Versus Watchful Waiting With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Symptomatic BPH

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dutasteride (Primary) ; Tamsulosin
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Acronyms CONDUCT
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 28 Nov 2020 Results of pooled meta-analysis from six clinical studies: ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT and CONDUCT published in the British Journal of Clinical Pharmacology
  • 26 Jul 2020 Results (n=10238) of pooled analysis of 6 studies (ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT, CONDUCT) assessing impact of early vs delayed initiation of dutasteride/tamsulosin combination therapy in benign prostatic hyperplasia patients with moderate to severe lower urinary tract symptoms, presented at the 35th Congress of the European Association of Urology.
  • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top